CSS
MCID: ESN020
MIFTS: 54

Eosinophilic Granulomatosis with Polyangiitis (CSS)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Eosinophilic Granulomatosis with Polyangiitis

MalaCards integrated aliases for Eosinophilic Granulomatosis with Polyangiitis:

Name: Eosinophilic Granulomatosis with Polyangiitis 54 60 38
Churg-Strauss Syndrome 54 60 74
Granulomatous Allergic Angiitis 54 60
Egpa 54 60
Allergic Angiitis and Granulomatosis 54
Allergic Granulomatous and Angiitis 54
Churg-Strauss Vasculitis 54
Allergic Granulomatosis 54
Css 54

Characteristics:

Orphanet epidemiological data:

60
eosinophilic granulomatosis with polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),<1/1000000 (Sweden),1-9/100000 (France),1-9/100000 (Sweden),<1/1000000 (United Kingdom),1-9/100000 (Norway),<1/1000000 (Spain),1-9/100000 (Australia),1-9/1000000 (Europe),1-9/100000 (Worldwide),<1/1000000 (Norway),1-9/1000000 (Germany),1-9/1000000 (Lithuania),1-9/1000000 (France),1-9/100000 (Germany),1-9/100000 (Japan); Age of onset: Adolescent,Adult,Elderly; Age of death: adolescent,adult,elderly,young Adult;

Classifications:



Summaries for Eosinophilic Granulomatosis with Polyangiitis

NIH Rare Diseases : 54 Eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small to medium sized blood vessels (vasculitis). The inflamed vessels can affect various organ systems including the lungs, gastrointestinal tract, skin, heart and nervous system. The exact cause of eosinophilic granulomatosis with polyangiitis is unknown, but it is thought to be an autoimmune disorder. Treatment may involve the use of glucocorticoids (steroids) and/or other immunosuppressive therapies. As of December 2017, mepolizumab (Nucala) became the first therapy approved specifically to treat eosinophilic granulomatosis with polyangiitis. When added to traditional steroid or immunosuppressive therapy, mepolizumab has been found to increase remission rate and time in remission for 50% of people with eosinophilic granulomatosis with polyangiitis.

MalaCards based summary : Eosinophilic Granulomatosis with Polyangiitis, also known as churg-strauss syndrome, is related to granulomatosis with polyangiitis and churg-strauss syndrome. An important gene associated with Eosinophilic Granulomatosis with Polyangiitis is IL27 (Interleukin 27), and among its related pathways/superpathways is Phagosome. The drugs Cyclophosphamide and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and neutrophil, and related phenotypes are weight loss and peripheral neuropathy

Wikipedia : 77 Eosinophilic granulomatosis with polyangiitis (EGPA), also known as allergic granulomatosis, is an... more...

Related Diseases for Eosinophilic Granulomatosis with Polyangiitis

Diseases related to Eosinophilic Granulomatosis with Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 granulomatosis with polyangiitis 30.6 FCGR3B IL27 MPO
2 churg-strauss syndrome 11.8
3 allergic angiitis 11.8
4 coffin-siris syndrome 1 11.4
5 autoimmune lymphoproliferative syndrome 11.2
6 granulomatous angiitis 10.6
7 glomerulonephritis 10.6
8 vasculitis 10.6
9 retinal artery occlusion 10.6
10 central retinal artery occlusion 10.5
11 wells syndrome 10.5
12 asthma 10.5
13 neuropathy 10.5
14 myocarditis 10.4
15 crescentic glomerulonephritis 10.4
16 hemorrhage, intracerebral 10.4
17 aspergillosis 10.4
18 thrombosis 10.4
19 hypereosinophilic syndrome 10.4
20 allergic bronchopulmonary aspergillosis 10.3
21 cholecystitis 10.3
22 cardiac conduction defect 10.3
23 gastroenteritis 10.3
24 acalculous cholecystitis 10.3
25 iga glomerulonephritis 10.3
26 purpura 10.3
27 rapidly progressive glomerulonephritis 10.3
28 dacryoadenitis 10.3
29 systemic polyarteritis nodosa 10.3
30 hepatitis 10.3
31 endocarditis 10.3
32 polyneuropathy 10.3
33 mononeuritis multiplex 10.3
34 peripheral nervous system disease 10.3
35 rere-related disorders 10.3
36 ige responsiveness, atopic 10.2
37 thrombophilia due to thrombin defect 10.2
38 anemia, autoimmune hemolytic 10.2
39 nonarteritic anterior ischemic optic neuropathy 10.2
40 focal segmental glomerulosclerosis 1 10.2
41 angina pectoris 10.2
42 arthritis 10.2
43 focal segmental glomerulosclerosis 10.2
44 hemolytic anemia 10.2
45 ischemic optic neuropathy 10.2
46 retinal vein occlusion 10.2
47 mononeuropathy 10.2
48 optic neuritis 10.2
49 branch retinal artery occlusion 10.2
50 prostatitis 10.2

Graphical network of the top 20 diseases related to Eosinophilic Granulomatosis with Polyangiitis:



Diseases related to Eosinophilic Granulomatosis with Polyangiitis

Symptoms & Phenotypes for Eosinophilic Granulomatosis with Polyangiitis

Human phenotypes related to Eosinophilic Granulomatosis with Polyangiitis:

60 33 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 weight loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0001824
2 peripheral neuropathy 60 33 hallmark (90%) Very frequent (99-80%) HP:0009830
3 sinusitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000246
4 congestive heart failure 60 33 hallmark (90%) Very frequent (99-80%) HP:0001635
5 autoimmunity 60 33 hallmark (90%) Very frequent (99-80%) HP:0002960
6 purpura 60 33 hallmark (90%) Very frequent (99-80%) HP:0000979
7 asthma 60 33 hallmark (90%) Very frequent (99-80%) HP:0002099
8 urticaria 60 33 hallmark (90%) Very frequent (99-80%) HP:0001025
9 vasculitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0002633
10 central nervous system degeneration 60 33 hallmark (90%) Very frequent (99-80%) HP:0007009
11 eosinophilia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001880
12 pulmonary infiltrates 60 33 hallmark (90%) Very frequent (99-80%) HP:0002113
13 hypertension 60 33 frequent (33%) Frequent (79-30%) HP:0000822
14 gait disturbance 60 33 frequent (33%) Frequent (79-30%) HP:0001288
15 dysphagia 60 33 frequent (33%) Frequent (79-30%) HP:0002015
16 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
17 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
18 arthralgia 60 33 frequent (33%) Frequent (79-30%) HP:0002829
19 hypertrophic cardiomyopathy 60 33 frequent (33%) Frequent (79-30%) HP:0001639
20 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
21 abnormality of the pleura 60 33 frequent (33%) Frequent (79-30%) HP:0002103
22 venous thrombosis 60 33 frequent (33%) Frequent (79-30%) HP:0004936
23 hypopigmented skin patches 60 33 frequent (33%) Frequent (79-30%) HP:0001053
24 hematuria 60 33 frequent (33%) Frequent (79-30%) HP:0000790
25 skin rash 60 33 frequent (33%) Frequent (79-30%) HP:0000988
26 abnormal pericardium morphology 60 33 frequent (33%) Frequent (79-30%) HP:0001697
27 tubulointerstitial nephritis 60 33 frequent (33%) Frequent (79-30%) HP:0001970
28 respiratory insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0002093
29 arthritis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001369
30 malabsorption 60 33 occasional (7.5%) Occasional (29-5%) HP:0002024
31 gastroesophageal reflux 60 33 occasional (7.5%) Occasional (29-5%) HP:0002020
32 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0000083
33 proteinuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000093
34 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
35 cranial nerve paralysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0006824
36 subcutaneous nodule 60 33 occasional (7.5%) Occasional (29-5%) HP:0001482
37 acrocyanosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001063
38 myocardial infarction 60 33 occasional (7.5%) Occasional (29-5%) HP:0001658
39 transient ischemic attack 60 33 occasional (7.5%) Occasional (29-5%) HP:0002326
40 hemiplegia/hemiparesis 60 33 occasional (7.5%) Occasional (29-5%) HP:0004374
41 myalgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003326
42 intestinal obstruction 60 33 occasional (7.5%) Occasional (29-5%) HP:0005214
43 glomerulopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0100820
44 hemoptysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002105
45 myocarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0012819
46 endocarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100584
47 cough 60 33 occasional (7.5%) Occasional (29-5%) HP:0012735
48 recurrent intrapulmonary hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0006535
49 papule 60 33 occasional (7.5%) Occasional (29-5%) HP:0200034
50 nasal polyposis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100582

MGI Mouse Phenotypes related to Eosinophilic Granulomatosis with Polyangiitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.13 FCGR3B IL27 MPO
2 immune system MP:0005387 8.8 FCGR3B IL27 MPO

Drugs & Therapeutics for Eosinophilic Granulomatosis with Polyangiitis

Drugs for Eosinophilic Granulomatosis with Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
2
Azathioprine Approved Phase 4,Phase 3,Early Phase 1 446-86-6 2265
3
leucovorin Approved Phase 4,Phase 2 58-05-9 6006 143
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Not Applicable 2921-57-5
6
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 302-25-0
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
10
Mycophenolic acid Approved Phase 4 24280-93-1 446541
11
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
13
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Not Applicable 2920-86-7
14 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antimetabolites Phase 4,Phase 3,Phase 2
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
18 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Folic Acid Antagonists Phase 4,Phase 2
22 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
23 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
25 Protective Agents Phase 4,Phase 3,Not Applicable
26 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
27 Dermatologic Agents Phase 4,Phase 2,Not Applicable
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
29 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
31 Antiemetics Phase 4,Phase 3,Not Applicable
32 Methylprednisolone Acetate Phase 4,Phase 3,Not Applicable
33 Vitamin B9 Phase 4,Phase 2
34 Folate Phase 4,Phase 2
35 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
36 Vitamin B Complex Phase 4,Phase 2
37 Anti-Infective Agents Phase 4,Not Applicable
38 Autonomic Agents Phase 4,Phase 3,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Prednisolone acetate Phase 4,Phase 3,Not Applicable
42 Antibiotics, Antitubercular Phase 4
43 Antitubercular Agents Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
48 Pharmaceutical Solutions Phase 3
49 Rho(D) Immune Globulin Phase 3
50 gamma-Globulins Phase 3

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
2 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
3 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
4 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
5 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
6 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
7 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
8 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
9 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
10 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
11 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
12 Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
13 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
14 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
15 Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Recruiting NCT02947945 Phase 2 Reslizumab
16 Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Recruiting NCT03010436 Phase 2 Benralizumab
17 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
18 Rituxan in Churg Strauss Syndrome With Renal Involvement Terminated NCT00424749 Phase 2 Rituximab;Prednisone
19 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
20 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
21 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
22 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
23 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
24 Survey of Patients With Idiopathic Orbital Inflammation Syndrome Unknown status NCT01443000
25 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Not Applicable Infliximab;Rituximab
26 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
27 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
28 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
29 Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
30 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
31 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
32 Eosinophilic Granulomatosis With Polyangiitis Cohort Recruiting NCT03036670
33 Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Recruiting NCT00315380
34 Pediatric Vasculitis Initiative Recruiting NCT02006134
35 VCRC Tissue Repository Recruiting NCT02967068
36 Vasculitis Pregnancy Registry Recruiting NCT02593565
37 One-Time DNA Study for Vasculitis Recruiting NCT01241305
38 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
39 Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Recruiting NCT03698071 Not Applicable
40 Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Recruiting NCT03373045
41 NUCALA® Special Drug Use Investigation (EGPA, Long-term) Active, not recruiting NCT03557060 Nucala
42 Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Active, not recruiting NCT01862068
43 VCRC Patient Contact Registry Patient-Reported Data Validation Study Enrolling by invitation NCT02190942
44 Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome Terminated NCT02728271 Early Phase 1

Search NIH Clinical Center for Eosinophilic Granulomatosis with Polyangiitis

Genetic Tests for Eosinophilic Granulomatosis with Polyangiitis

Anatomical Context for Eosinophilic Granulomatosis with Polyangiitis

MalaCards organs/tissues related to Eosinophilic Granulomatosis with Polyangiitis:

42
Skin, Heart, Neutrophil, T Cells, Colon, Bone, Small Intestine

Publications for Eosinophilic Granulomatosis with Polyangiitis

Articles related to Eosinophilic Granulomatosis with Polyangiitis:

(show top 50) (show all 549)
# Title Authors Year
1
Chronic pulmonary aspergillosis may cause eosinophilic granulomatosis with polyangiitis via allergic bronchopulmonary aspergillosis. ( 30800324 )
2019
2
Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. ( 30652675 )
2019
3
Immunoglobulin G4-Related Disease Presenting with Clinical Similarity to Churg-Strauss Syndrome. ( 30772966 )
2019
4
Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: A case report. ( 30603598 )
2019
5
IgG4-Related Disease and Eosinophilic Granulomatosis with Polyangiitis: Similarity or Coexistence? ( 30772965 )
2019
6
Childhood-onset Eosinophilic Granulomatosis with Polyangiitis with a Vulvar Granuloma: A Case Report and Review of the Literature. ( 30904627 )
2019
7
Anti-neutrophil cytoplasmic antibody-positive eosinophilic granulomatosis with polyangiitis: can it cause membranous nephropathy? ( 30907692 )
2019
8
Flare of eosinophilic granulomatosis with polyangiitis related to pregnancy: Case report and review of the literature. ( 30456168 )
2019
9
Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review. ( 30554307 )
2019
10
Pregnancy in a patient with eosinophilic granulomatosis with polyangiitis. ( 30634882 )
2019
11
A Perianal Mass Associated With Eosinophilic Granulomatosis With Polyangiitis: Challenge. ( 30640763 )
2019
12
Eosinophilic granulomatosis with polyangiitis in children: Data from the French RespiRareAr cohort. ( 29943913 )
2018
13
Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies. ( 29611001 )
2018
14
Multiple Cerebral Infarctions Due to Patent Foramen Ovale in a Patient with Eosinophilic Granulomatosis with Polyangiitis. ( 29373226 )
2018
15
Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. ( 29908086 )
2018
16
A Case of dilated Cardiomyopathy with Eosinophilic Granulomatosis with Polyangiitis in which Active Myocardial Inflammation was Only Detected by Endomyocardial Biopsy. ( 29709930 )
2018
17
Mepolizumab Treatment of Pediatric Eosinophilic Granulomatosis With Polyangiitis. ( 29466544 )
2018
18
Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. ( 29857992 )
2018
19
Eosinophilic granulomatosis with polyangiitis and laryngeal involvement: review of the literature and a cross-sectional prospective experience. ( 29888684 )
2018
20
Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis With Polyangiitis. ( 29652700 )
2018
21
A Rare Case of Eosinophilic Granulomatosis with Polyangiitis Associated with Cryoglobulinemia Presenting with a Bullous Skin Eruption of the Lower Limbs. ( 29560002 )
2018
22
Histopathological Findings and Increased D-Dimer Are Predictive Factors of Systemic Thromboses in Eosinophilic Granulomatosis With Polyangiitis. ( 29979194 )
2018
23
Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. ( 29393242 )
2018
24
Polyps, grommets and eosinophilic granulomatosis with polyangiitis. ( 29310745 )
2018
25
Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis. ( 29907668 )
2018
26
Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review. ( 29766394 )
2018
27
HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. ( 29754328 )
2018
28
Eosinophilic granulomatosis with polyangiitis: A case report. ( 29428428 )
2018
29
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. ( 29637936 )
2018
30
Eosinophilic Granulomatosis with Polyangiitis Manifested by Cholecystitis and Mononeuritis Multiplex: A Case Report. ( 29892153 )
2018
31
Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report. ( 29564565 )
2018
32
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2018
33
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. ( 29936437 )
2018
34
Development of Hypertrophic Pachymeningitis in a Patient With Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis With Polyangiitis. ( 29485545 )
2018
35
Intracranial vasculitis in eosinophilic granulomatosis with polyangiitis. ( 29901786 )
2018
36
Silent acute myocarditis in eosinophilic granulomatosis with polyangiitis. ( 30641540 )
2018
37
Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. ( 30170804 )
2018
38
Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis: Exuberant Classic Clinical Picture of a Rare Disease. ( 30057533 )
2018
39
Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature. ( 30134390 )
2018
40
Churg-Strauss Syndrome Presenting As Acute Necrotizing Eosinophilic Myocarditis. Concise review of the literature. ( 30179138 )
2018
41
Differential Diagnosis of Churg-Strauss Syndrome with Tingling Sensation and Weakness of the Lower Extremities. ( 30719419 )
2018
42
Usefulness of Cardiac Magnetic Resonance in the Diagnosis of Löffler Endocarditis Secondary to Eosinophilic Granulomatosis with Polyangiitis. ( 30146590 )
2018
43
Eosinophilic granulomatosis with polyangiitis in a continuous flow left ventricular assist device patient: a case report and review of literature. ( 30684748 )
2018
44
A Case of Eosinophilic Granulomatosis with Polyangiitis Complicated with A IgG4 Related Disease Like Symptoms. ( 30693119 )
2018
45
Portal Vein Thrombosis and Thrombocytopenia in Eosinophilic Granulomatosis with Polyangiitis: A Paradox? ( 30755990 )
2018
46
Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban. ( 29998056 )
2018
47
Conjunctival Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) in a Young Adult Male With Persistent Ptosis. ( 30048387 )
2018
48
Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon et al. ( 30054370 )
2018
49
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report. ( 30073971 )
2018
50
Eosinophilic Myocarditis Demonstrated Using Cardiac Magnetic Resonance Imaging in a Patient with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Disease). ( 30112268 )
2018

Variations for Eosinophilic Granulomatosis with Polyangiitis

Expression for Eosinophilic Granulomatosis with Polyangiitis

Search GEO for disease gene expression data for Eosinophilic Granulomatosis with Polyangiitis.

Pathways for Eosinophilic Granulomatosis with Polyangiitis

Pathways related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 FCGR3B MPO

GO Terms for Eosinophilic Granulomatosis with Polyangiitis

Cellular components related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 8.8 FCGR3B IL27 MPO

Biological processes related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 8.62 FCGR3B MPO

Sources for Eosinophilic Granulomatosis with Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....